$30.50
arrow_drop_up1.66%Key Stats | |
---|---|
Open | $30.07 |
Prev. Close | $30.02 |
EPS | -1.91 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 29.93 | 30.99 |
52 Week Range | 24.67 | 45.58 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -1.91 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab
Immunovant Provides Update on Graves’ Disease Development Program
Thyroid Eye Disease Market to Accelerate Substantially by 2034, Assesses DelveInsight | Key Companies Developing ... - GlobeNewswire
Immunovant (IMVT) Down 1.6% Since Last Earnings Report: Can It Rebound?
Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024